Ultralife (ULBI) Projected to Announce Quarterly Earnings on Friday

Ultralife (NASDAQ:ULBI) is expected to announce its Q2 2026 results before the market opens on Friday, August 7th. Analysts expect the company to post earnings of $0.19 per share and revenue of $55.00 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 7, 2026 at 8:00 AM ET.

Ultralife (NASDAQ:ULBI) last issued its earnings results on Friday, May 8th. The technology company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.18). Ultralife had a negative net margin of 4.37% and a positive return on equity of 1.15%. The company had revenue of $47.45 million for the quarter, compared to analysts’ expectations of $52.40 million.

Ultralife Trading Down 0.2%

ULBI stock traded down $0.01 during midday trading on Wednesday, hitting $5.47. The company had a trading volume of 8,709 shares, compared to its average volume of 42,983. The company has a current ratio of 2.56, a quick ratio of 1.23 and a debt-to-equity ratio of 0.34. Ultralife has a 52 week low of $4.90 and a 52 week high of $8.25. The stock’s 50 day moving average price is $6.13 and its 200 day moving average price is $6.36. The stock has a market cap of $91.13 million, a price-to-earnings ratio of -10.94 and a beta of 0.80.

Insiders Place Their Bets

In other news, Director Bradford T. Whitmore purchased 67,302 shares of Ultralife stock in a transaction that occurred on Tuesday, May 26th. The shares were bought at an average cost of $6.81 per share, with a total value of $458,326.62. Following the completion of the purchase, the director directly owned 2,050,637 shares in the company, valued at approximately $13,964,837.97. This trade represents a 3.39% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders acquired 108,878 shares of company stock valued at $714,928 over the last 90 days. 42.90% of the stock is owned by corporate insiders.

Institutional Trading of Ultralife

A number of hedge funds have recently modified their holdings of the business. Empowered Funds LLC purchased a new stake in shares of Ultralife in the 4th quarter worth about $44,000. Lazard Asset Management LLC lifted its position in Ultralife by 1,650.0% during the 2nd quarter. Lazard Asset Management LLC now owns 5,565 shares of the technology company’s stock valued at $49,000 after acquiring an additional 5,247 shares during the period. Prelude Capital Management LLC purchased a new position in Ultralife during the 3rd quarter valued at about $71,000. Jane Street Group LLC bought a new stake in Ultralife during the fourth quarter worth about $75,000. Finally, Jones Financial Companies Lllp grew its holdings in Ultralife by 1,428.7% in the first quarter. Jones Financial Companies Lllp now owns 15,287 shares of the technology company’s stock worth $82,000 after purchasing an additional 14,287 shares during the period. Institutional investors own 30.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Ultralife from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Ultralife Company Profile

Ultralife Corporation (NASDAQ: ULBI) develops, manufactures and sells a broad range of energy and communications products for defense, medical, automotive and consumer electronics markets. The company operates through two primary segments: Power Systems and Communications Systems. In its Power Systems segment, Ultralife produces lithium-ion rechargeable cells and battery packs, primary lithium batteries, alkaline and rechargeable battery packs, chargers and battery accessories designed to meet demanding performance and safety requirements.